A ntiplatelet agents are prescribed for the prevention of cardiovascular events, especially in patients who have undergone percutaneous coronary intervention (PCI) and surgical procedures. The physiologic stress of surgery begins an acute phase reaction characterized by increasing platelet adhesiveness and decreased fibrinolysis. 1, 2 In the postoperative setting, up to half of myocardial infarctions can be attributed to the disruption and thrombosis of an unstable plaque. [3] [4] [5] Two of the most common antiplatelet agents that orthopedic surgeons encounter are acetylsalicylic acid (ASA [aspirin] ) and clopidogrel. Acetylsalicylic acid is commonly used to prevent both cardiovascular and cerebrovascular disease in the general population. 6, 7 Acetylsalicylic acid irreversibly blocks the formation of thromboxane A2 in platelets and inhibits platelet aggregation through inhibition of cyclooxygenase (COX)-1 enzyme. 8 Clopidogrel is normally prescribed following acute coronary syndrome (ACS), cerebrovascular attack (CVA), and PCI. 9 There are conflicting reports regarding postoperative bleeding risks associated with discontinuation of antiplatelet therapy at least 7 days preoperatively.
Most of the studies in the spine literature are based on surveys or anecdotal evidence. The majority of surgeons discontinue therapy 7 days preoperatively, but this varies widely from 5 to 21 days. The purpose of this retrospective study was to assess whether chronic antiplatelet use is associated with increased intraoperative blood loss, need for transfusion, and perioperative complications. Of 454 patients who underwent elective lumbar spinal surgery, 85 were on antiplatelet therapy and 369 were not. All patients stopped antiplatelet therapy at least 7 days preoperatively with approval from their cardiologist or primary care provider. Multiple regression analysis was performed and corrected for age, sex, antiplatelet therapy, number of levels decompressed/fused/instrumented, preoperative hematocrit, and postoperative hematocrit. Results showed that preoperative antiplatelet therapy, despite at least 7 days of discontinuation, is a statistically significant predictor (P=.04) of increased intraoperative blood loss. Blood transfusion was not associated with antiplatelet use but was associated with the number of levels fused, age, and low preoperative hematocrit (all P<.01). There were no recorded complications in either group. The authors conclude that antiplatelet therapy is associated with an increased risk of intraoperative blood loss in spine patients despite discontinuation at least 7 days preoperatively, but the clinical significance of this is unclear given the lack of association with blood transfusions and perioperative complications. [Orthopedics. 2016; 39(4):e695-e700.]
The irreversible mechanisms of these drugs render their half-lives clinically irrelevant. 11 It takes 7 to 10 days after discontinuation of either of these agents for the platelet pool to replenish and regain full functionality, which is based on work that has shown that 10% to 14% of normal platelet function is returned each day following discontinuation. [12] [13] [14] In the setting of elective orthopedic procedures, these drugs create a unique challenge for surgeons who want to balance the risk of perioperative bleeding against the risk of coronary artery or intracoronary stent thrombosis. Blood loss in spinal decompression and fusion surgery has been documented to be upwards of 2 L. 15 This can necessitate transfusion of blood products for certain patients, which in turn leads to increased risk of morbidity and increased costs. 16, 17 Furthermore, in decompression procedures, a postoperative epidural hematoma may be a neurologically devastating complication. [18] [19] [20] [21] Several case reviews report that this risk is much more than just theoretical for patients on aspirin, clopidogrel, or a combination of the two. [22] [23] [24] [25] [26] [27] For these reasons, spinal surgeons have a vested interest in seeking out any variables that they may be able to adjust to mitigate these risks while still doing what is ultimately best for the overall health of the patient. It has been suggested that it may be possible to continue antiplatelet agents for smaller procedures such as simple diskectomies, but for more extensive operations such as decompressions and fusions it is likely safest to discontinue antiplatelet medication. 9, 28 To date, few studies have assessed the optimal timing of antiplatelet drug cessation preoperatively-in particular, whether stopping 7 to 10 days preoperatively affects bleeding, morbidity, and mortality. [29] [30] [31] Most of the orthopedic literature on the subject is based on surveys or anecdotal evidence, with the majority of surgeons reporting that they discontinue the medications 7 days preoperatively. However, this ranges widely from 5 to 21 days. 32 To further evaluate this topic, the current authors chose to examine their own patient population to determine what, if any, effect antiplatelet agents had on intraoperative blood loss and perioperative transfusion requirements. The purpose of this study was to determine whether blood loss and transfusion requirements in patients on antiplatelet therapy were different from those in patients not on antiplatelet therapy when anticoagulated patients were required to discontinue antiplatelet agents at least 7 days preoperatively. The authors hypothesized that patients on antiplatelet therapy would have increased intraoperative blood loss and transfusion requirements, despite strict adherence to discontinuation of these agents at least 7 days preoperatively.
Materials and Methods
Following institutional review board approval, a retrospective review of adults who underwent elective lumbar spinal surgery at a high-volume tertiary care center under the care of a single surgeon (N.U.A.) were screened for possible enrollment in this study. Patients undergoing surgery for infectious processes, malignancies, or trauma were excluded from the study. Patients with underlying coagulopathies or neoplastic disease or those on anticoagulants other than antiplatelet agents, such as warfarin, were also excluded from the study. These study parameters yielded 454 patients undergoing elective lumbar spinal surgery, 85 of whom were on antiplatelet therapy preoperatively and 369 of whom were control patients. Patient demographics and procedures performed can be seen in Table 1 and Table 2 , respectively. The electronic medical records and physical charts were reviewed by an independent observer (E.S.Y.) who was not involved in patient care. All patients stopped antiplatelet therapy at least 7 days preoperatively with approval from their cardiologist or primary care provider.
Operative outcomes such as intraoperative estimated blood loss and intraoperative transfusion were recorded. Postoperative transfusion and total number of blood products used (both intra-and postoperatively) were also recorded. Complications such as myocardial infarcts/events and CVA events were recorded, if present.
Statistical analysis using 1-way analysis of variance and t tests to compare patients on clopidogrel and aspirin with the control population was performed to evaluate quantitative and qualitative factors. To determine the effect on intraoperative blood loss and blood units transfused, a multiple linear regression model that accounted for all confounding variables, such as antiplatelet use, age, sex, number of levels decompressed, number of levels fused, number of levels instrumented, preoperative hematocrit, and postoperative hematocrit, was used. All P values less than .05 were considered statistically significant. Statistical analysis was performed using Statgraphics Centurion XVI (Statpoint Technologies, Inc, Warrenton, Virginia).
results
After correcting for age, sex, antiplatelet therapy, number of levels decompressed/fused/instrumented, preoperative hematocrit, and postoperative hematocrit, multiple regression analysis showed that preoperative antiplatelet therapy was a statistically significant predictor (P=.04) of intraoperative blood loss despite discontinuation of the drugs at least 7 days preoperatively. Also, the number of levels decompressed, number of levels fused, and number of levels instrumented were statistically significant predictors (P<.01) of intraoperative blood loss. When examining the total number of blood units transfused (intra-and postoperatively), the multiple linear regression model showed that the number of transfused units was associated with number of levels fused, age of the patient, and low preoperative hematocrit (all P<.01). The significant variables in each of these multiple regression analyses can be further examined in Table 2 .
To further analyze the effect that the different antiplatelet therapies had on intraoperative blood loss, a longer operation was corrected for by standardizing estimated blood loss to levels decompressed, fused, and/or instrumented. Results of singlevariable analysis for pre-and postoperative hematocrit, as well as the number of levels decompressed, fused, and/or instrumented, can be seen in Table 3 . In the decompression group, there was increased blood loss in patients on clopidogrel. In the fusion and instrumented groups, patients on aspirin were found to have higher levels of blood loss than those in both the clopidogrel and control groups. These data can be found in Table 4 and Table 5 . There were no recorded complications such as deep venous thrombosis, pulmonary embolism, myocardial infarct, CVA events, or epidural hematoma for patients on antiplatelet therapy and those who were not.
discussion
The possibility of severe neurologic damage from increased bleeding after lumbar surgery is well documented in case studies of patients on antiplatelet therapy. 22, 23, [25] [26] [27] [33] [34] [35] For these reasons, any significant increase in bleeding may be considered unacceptable. 27 This risk must be balanced with the fact that the surgical systemic inflammatory syndrome and acute-phase reaction that results from undergoing surgery have been shown to in- Past research has suggested that 7 days is the minimum amount of time required to reverse the effect of antiplatelet medications. 12, 14, 39, 40 The current authors sought to determine whether patients who discontinue these drugs at least 7 days preoperatively experience significant blood loss or whether 7 days is adequate to prevent bleeding and complications related to it. Multiple regression analysis showed that antiplatelet therapy is a predictor of significant intraoperative blood loss (P=.04) in elective lumbar surgery, even in patients who discontinue these medications at least 7 days preoperatively. Other factors, such as number of levels decompressed, fused, and/or instrumented, were also significant predictors. This is more intuitive because each increased level exposes the patient to prolonged operative times and increased surgical bleeding, and this result has been supported by previous research. 41 To date, there is no consensus on whether antiplatelet medications need to be discontinued preoperatively, and the controversy continues with many contradictions and confounders in the literature. Much of the research on the subject has been performed in nonorthopedic patients, and within the orthopedic realm the focus is mainly on trauma patients and those undergoing elective arthroplasty. One such study is a large meta-analysis of approximately 50,000 patients, which found that there was an increased overall bleeding risk (risk ratio=1.5) with aspirin therapy, but this degree of bleeding was not clinically significant because it did not require intervention. 30, 31 In the trauma literature, Chechik et al 42 demonstrated that the use of antiplatelet drugs was associated with increased perioperative blood loss and prolonged operative time but did not increase mortality. Nydick et al 43 also found no increase in serious complications or transfusion requirements in patients on these medications, but they did not comment on blood loss.
Although there is a general paucity of literature on antiplatelet therapy and its effects on perioperative blood loss and transfusion requirements in lumbar surgery, there has been some recent research with mixed results. Kang et al 44 examined patients who had undergone lumbar fusion and had discontinued antiplatelet therapy at least 7 days preoperatively. They showed that although there was no increase in intraoperative blood loss, there was a significant difference in postoperative blood drainage, which resulted in increased complications and increased transfusion requirements. 44 Park et al 45 took this further by assigning patients to 2 separate groups: those who had discontinued antiplatelets 3 to 7 days prior to undergoing lumbar fusion and those who had discontinued them at least 7 days preoperatively. Their results showed that only patients who discontinued antiplatelet therapy less than 7 days preoperatively had increased blood loss and postoperative drainage. However, further examination of their results showed that blood loss in the antiplatelet groups was significantly less than that in the control groups. These results may have been skewed because of the small size of their study (n=7 and n=20 for antiplatelet groups). 45 Last year, Park et al 46 published results showing that antiplatelet use significantly increased the risk of bleeding in patients undergoing lumbar fusion at 2 or more levels, despite discontinuation of therapy at least 1 week preoperatively.
The current study's findings are more in line with those of Kang et al 44 and Park et al. 45 A significant increase in intraoperative blood loss was found in patients on chronic antiplatelet therapy despite discontinuation of these drugs at least 7 days before undergoing lumbar surgery. Other factors correlated with increased bleeding included number of levels decompressed, fused, and instrumented, which has been documented in past research. 41, 47 Although the blood loss was statistically significant, it is unclear whether this is clinically so. There was no increase in postoperative complications, and there were no epidural hematomas in the group of 85 patients previously on antiplatelet therapy.
This study is not without limitations. First, this is a retrospective cohort analysis and thus subject to the inherent limitations of this design. Although the authors are not aware of any studies that examine the effects of clopidogrel only in association with spinal surgery, this study had a relative shortage of patients on clopidogrel (n=13) compared with aspirin (n=72); therefore, both of these cohorts were examined as a single group. The authors justify this by noting that, although the mechanisms of action of the 2 medications are different, the resultant effect and duration of action are considered to be the same. 12, 14, 30 Both are irreversible inhibitors of platelet function and require platelet pool replenishment prior to normal platelet function. This study has a larger patient population than many previous studies on this topic, which the authors believe helps lend credibility to this work. Another limitation is that during the study, operative time was not documented and was therefore not able to be applied to the statistical analysis.
conclusion Antiplatelet therapy appears to increase intraoperative blood loss in lumbar surgery, even when the medication is discontinued at least 7 days preoperatively. The clinical significance of this is unclear because no increase was found in the need for blood transfusions or in serious complications such as ACS, CVA, epidural hematoma, spinal cord compression, or cauda equina syndrome. This study demonstrates that cessation of antiplatelet therapy 7 days preoperatively may be sufficient to minimize bleeding complications associated with antiplatelet therapy. However, each patient should be evaluated on an individual basis in coordination with his or her cardiologist to determine whether he or she is medically cleared to discontinue antiplatelet therapy. It is also imperative that the surgeon inform the patient about the risk of bleeding and possible postoperative complications that may be associated with it.
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